Tamara Gorman
Family · Terre Haute, INNPI 1154953099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 890 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $4,360 and has fallen 69.9% since, to $1,310 in 2025. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 890 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$2K
- Tandem Diabetes Care, Inc.$2K
- Novo Nordisk$2K
- AstraZeneca$1K
- Amgen$1K
- Lilly USA, LLC$1K
- plus $7K from 34 others
What the payments were for
- Travel & lodging$9556%
- Food & beverage$15,11593%
- Education$200%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 136 | $1,969 |
| Tandem Diabetes Care, Inc. | 18 | $1,819 |
| Novo Nordisk | 144 | $1,536 |
| AstraZeneca(2 entities) | 39 | $1,373 |
| Amgen(2 entities) | 52 | $1,065 |
| Lilly USA, LLC | 62 | $1,003 |
| Corcept Therapeutics | 62 | $997 |
| Dexcom, Inc. | 39 | $681 |
| Bayer | 39 | $599 |
| Medtronic | 12 | $443 |
| Esperion Therapeutics, Inc. | 37 | $425 |
| Abbott | 21 | $393 |
| Boehringer Ingelheim | 23 | $392 |
| Novartis | 23 | $392 |
| Xeris Pharmaceuticals, Inc. | 20 | $373 |
| AbbVie | 19 | $310 |
| Recordati_rare_diseases_inc. | 16 | $300 |
| Radius Health, Inc. | 18 | $280 |
| Mannkind Corporation | 12 | $267 |
| Sanofi-aventis U.S. LLC | 14 | $228 |
| UCB, Inc. | 9 | $185 |
| Antares Pharma, Inc. | 12 | $165 |
| Amarin Pharma, Inc. | 14 | $152 |
| Cequr Corporation | 2 | $111 |
| Lifescan, Inc. | 7 | $103 |
| Merck | 7 | $91 |
| Amneal Pharmaceuticals LLC | 4 | $69 |
| Kyowa Kirin, Inc. | 3 | $65 |
| IBSA Pharma Inc. | 4 | $64 |
| Sequel Med Tech, LLC | 3 | $62 |
| Currax Pharmaceuticals LLC | 4 | $54 |
| EUSA Pharma (US) LLC | 3 | $47 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| BETA Bionics, Inc. | 2 | $34 |
| Zealand Pharma US, Inc. | 2 | $29 |
| Halozyme Inc | 2 | $28 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$1,589
- FARXIGA$413
- Repatha$251
- Strensiq$225
- DEXCOM G7 GSS (161)$157
- FREESTYLE LIBRE 3$145
- Omnipod$110
How this compares
$16,209 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 457 | $501,984 |
| MounjaroTirzepatide | 426 | $467,582 |
| JardianceEmpagliflozin | 255 | $194,666 |
| RybelsusSemaglutide | 119 | $140,139 |
| FarxigaDapagliflozin Propanediol | 88 | $71,475 |
| TrulicityDulaglutide | 65 | $71,044 |
| Repatha SureclickEvolocumab | 74 | $56,446 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $39,596 |
| KerendiaFinerenone | 36 | $33,560 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 16 | $29,562 |
| TradjentaLinagliptin | 42 | $27,746 |
| JanuviaSitagliptin Phosphate | 39 | $26,941 |
| VascepaIcosapent Ethyl | 50 | $21,909 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $20,290 |
| Bydureon BciseExenatide Microspheres | 15 | $19,587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $1,536 | $661,899606 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,003 | $550,389532 claims |
| Boehringer IngelheimJardiance, Tradjenta | $392 | $222,412297 claims |
| AstraZenecaFarxiga | $1,373 | $71,47588 claims |
| BayerKerendia | $599 | $33,56036 claims |
| MerckJanuvia | $91 | $26,94139 claims |
| AbbVieLinzess, Synthroid | $310 | $17,30691 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $69 | $1,390148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Terre Haute
- Stephanie ArnoldTerre Haute$52K
- Daxton DuncanTerre Haute$31K
- Melinda FuquaTerre Haute$19K
- Kathy BannonTerre Haute$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.